Use of Angiotensin Receptor Blocker is Associated with Improved 1 Year Mortality in Heart Failure with Mid-Range Ejection Fraction
Open Access
- 22 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (2) , 1438-1445
Abstract
Aims Current evidence about the effect of angiotensin receptor blocker (ARB) on the outcome of heart failure with mid‐range ejection fraction (HFmrEF) is lacking. We aim to assess the association between use of ARB and 1 year all‐cause mortality after hospitalization for HFmrEF. Methods and results We analysed the data of patients with ejection fraction of 40–49% in China Patient‐centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study; 4907 patients hospitalized for heart failure from 52 Chinese hospitals were enrolled from August 2016 to May 2018. Use of ARB was determined by prescriptions at discharge. Patients who died during hospitalization or were using angiotensin‐converting enzyme inhibitors at discharge were excluded. The association between the use of ARB and outcome was assessed using stabilized inverse probability of treatment weighting‐adjusted Kaplan–Meier and Cox regression analyses. A total of 701 patients with HFmrEF were included for analysis. The mean age was 66.4 ± 12.8 years, and 267 (38.1%) were female. Of them, 244 were treated (34.8%) with ARB. During the 1 year follow‐up period, patients treated with ARB had lower all‐cause mortality compared with untreated patients (11.5% vs. 21.9%, P = 0.0005). Inverse probability of treatment weighting‐adjusted Cox regression analysis showed that use of ARB was associated with significantly reduced all‐cause mortality (adjusted hazard ratio 0.44, 95% confidence interval 0.28–0.69, P = 0.0004). Conclusions Among patients hospitalized for HFmrEF, the use of ARB was associated with lower 1 year mortality after discharge.Keywords
Funding Information
- Ministry of Science and Technology (2018YFC1312400)
- Ministry of Science and Technology (2018YFC1312401)
- Ministry of Science and Technology (2015BAI12B02)
- Chinese Academy of Medical Sciences (2020-I2M-2-007)
- Chinese Academy of Medical Sciences (2016-I2M-2-004)
- Chinese Academy of Medical Sciences (2017-I2M-2-002)
- Ministry of Education of the People's Republic of China (B16005)
- Peking Union Medical College (2018-1002-01-12)
- Peking Union Medical College
- Peking Union Medical College
- Ministry of Education of the People's Republic of China (B16005)
- Peking Union Medical College (2018‐1002‐01‐12)
This publication has 32 references indexed in Scilit:
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection FractionJAMA, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart FailureArchives of internal medicine (1960), 2011
- Analytical Review of the Evidence for Renoprotection by Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease – A Call for CautionNephron Clinical Practice, 2009
- Adjusted survival curves with inverse probability weightsComputer Methods and Programs in Biomedicine, 2004
- Renal Insufficiency and Heart FailureCirculation, 2004
- Polypharmacy and comorbidity in heart failureBMJ, 2003
- Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failureAmerican Heart Journal, 2003